Use of Linezolid in the treatment of surgical infectious complications under antibiotic resistance

Authors

  • O A Nazarchuk National Pirogov Memorial Medical University, Vinnytsia
  • V L Vitkovskiy National Pirogov Memorial Medical University, Vinnytsia
  • Yu M Babina National Pirogov Memorial Medical University, Vinnytsia

DOI:

https://doi.org/10.31636/prmd.v3i2.5

Keywords:

Linezolid, vancomycin-resistant enterococci (VRE), methicillin-resistant Staphylococcus aureus (MRSA)

Abstract

Linezolid – a first representative of the new class of synthetic antibiotics oxazolidones. Its antibacterial spectrum includes Gram-positive microorganisms, including multi-resistant strains. Its unique mechanism of action conditions absence of cross-resistance with other antibiotics. This drug is presented in peroral and parenteral forms. Unlike vancomycin, it has optimal pharmacokinetic profile. Linezolid was approved by Food and Drug Administration (FDA) in 2000 for the treatment of the following diseases: hospital- and community-acquired pneumonia, skin and soft tissue infections with or without complications caused by Gram-positive bacteria, vancomycin-resistant enterococci and pneumococcal meningitis, caused by penicillin-resistant Streptococcus pneumoniae.

Downloads

Download data is not yet available.

References

Society for Healthcare Epidemiology of America, Infectious Dis-eases Society of America, Pediatric Infectious Diseases Society. Policy statement on antimicrobial stewardship by the society for healthcare epidemiology of America (SHEA), the infectious diseas-es society of America (IDSA), and the pediatric infectious diseases society (PIDS). Infect Control Hosp Epidemiol. 2012;33(4):322–327

Uttley AC, Collins CH, naidoo J, George RC. Vancomycin-resistant enterococci. The Lancet [Internet]. Elsevier BV; 1988 Jan;331(8575–8576):57–8. Available from: https://doi.org/10.1016/s0140–6736(88)91037–9

Zhao C, Sun H, Wang H, Liu Y, Hu B, Yu Y, et al. Antimicrobial re-sistance trends among 5608 clinical Gram-positive isolates in China: results from the Gram-Positive Cocci Resistance Surveillance program (2005–2010). Diagnostic Microbiology and Infectious Disease [Internet]. Elsevier BV; 2012 Jun;73(2):174–81. Available from: https://doi.org/10.1016/j.diagmicrobio.2012.03.003

Cattoir V, Leclercq R. Twenty-five years of shared life with van-comycin-resistant enterococci: is it time to divorce? Journal of Antimicrobial Chemotherapy [Internet]. Oxford University Press (OUP); 2012 Dec 2;68(4):731–42. Available from: https://doi.org/10.1093/jac/dks469

Shukla BS, Gauthier TP, Correa R, Smith L, Abbo L. Treatment considerations in vancomycin-resistant enterococcal bacteremia: daptomycin or linezolid? A review. International Journal of Clin-ical Pharmacy [Internet]. Springer Science and Business Media LLC; 2013 Jul 27;35(5):697–703. Available from: http://dx.doi.org/10.1007/s11096–013–9825–5

DiazGranados CA, Zimmer SM, Mitchel K, Jernigan JA. Compar-ison of Mortality Associated with Vancomycin-Resistant and Vancomycin-Susceptible Enterococcal Bloodstream Infections: A Meta-analysis. Clinical Infectious Diseases [Internet]. Oxford Uni-versity Press (OUP); 2005 Aug 1;41(3):327–33. Available from: http://dx.doi.org/10.1086/430909

Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis. 2006; 42: 25–34.

Manian FA, Meyer PL, Setzer J, Senkel D. Surgical Site Infections Associated with Methicillin ResistantStaphylococcus aureus:Do Postoperative Factors Play a Role? Clinical Infectious Diseases [Internet]. Oxford University Press (OUP); 2003 Apr;36(7):863–8. Available from: http://dx.doi.org/10.1086/368195

Peppard WJ, Weigelt JA. Role of linezolid in the treatment of compli-cated skin and soft tissue infections. Expert Review of Anti-infec-tive Therapy [Internet]. Informa UK Limited; 2006 Jun;4(3):357–66. Available from: http://dx.doi.org/10.1586/14787210.4.3.357

Batts DH. Linezolid-a new option for treating Gram-positive infec-tions. Oncology. 2000;14(8,6):23–29

Vashchuk VV, Kyryk TP, Gerych GI, Khomchenko TV. Oxazolid-inones are an alternative to glycopeptides in the treatment of gram-positive surgical infections caused by methicillin-resistant Staphylococcus aureus. [Internet]. 06/12/2018 Available from: https://health-ua.com/article/37743-oksazoldinoni--alternati-va-glkopeptidam--ulkuvann-grampozitivno-hrurgchno-n

Zurenko G. Oxazolidinones: a new class of antibacterials. Cur-rent Opinion in Pharmacology [Internet]. Elsevier BV; 2001 Oct 1;1(5):470–6. Available from: http://dx.doi.org/10.1016/s1471–4892(01)00082–0

Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the Treatment of Multidrug Resistant, Gram-Positive Infections: Experience from a Compassionate Use Program. Clinical Infectious Diseases [Internet]. Oxford University Press (OUP); 2003 Jan 15;36(2):159–68. Available from: http://dx.doi.org/10.1086/345744

Faella F, Pagliano P, Fusco U, Attanasio V, Conte M. Combined treatment with ceftriaxone and linezolid of pneumococcal meningitis: a case series including penicillin-resistant strains. Clin-ical Microbiology and Infection [Internet]. Elsevier BV; 2006 Apr;12(4):391–4. Available from: http://dx.doi.org/10.1111/j.1469–0691.2006.01352.x

Perry CM, Jarvis B. Linezolid. Drugs [Internet]. Springer Science and Business Media LLC; 2001;61(4):525–51. Available from: http://dx.doi.org/10.2165/00003495–200161040–00008

Li Y, Xu W. Efficacy and safety of linezolid compared with other treatments for skin and soft tissue infections: a meta-analysis. Bio-science Reports [Internet]. Portland Press Ltd.; 2018 Feb 13;38(1). Available from: http://dx.doi.org/10.1042/bsr20171125

Stevens DL, Smith LG, Bruss JB, McConnell-Martin MA, Duvall SE, Todd WM, et al. Randomized Comparison of Linezolid (PnU-100766) versus Oxacillin-Dicloxacillin for Treatment of Com-plicated Skin and Soft Tissue Infections. Antimicrobial Agents and Chemotherapy [Internet]. American Society for Microbiol-ogy; 2000 Dec 1;44(12):3408–13. Available from: http://dx.doi. org/10.1128/aac.44.12.3408–3413.2000

Stevens DL, Smith LG, Bruss JB, McConnell-Martin MA, Duvall SE, Todd WM, et al. Randomized Comparison of Linezolid (PnU-100766) versus Oxacillin-Dicloxacillin for Treatment of Com-plicated Skin and Soft Tissue Infections. Antimicrobial Agents and Chemotherapy [Internet]. American Society for Microbiol-ogy; 2000 Dec 1;44(12):3408–13. Available from: http://dx.doi. org/10.1128/aac.44.12.3408–3413.2000

Rubinstein E, Cammarata SK, Oliphant TH, Wunderink RG. Linezol-id (PnU-100766) versus Vancomycin in the Treatment of Hospitalized Patients with nosocomial Pneumonia: A Randomized, Double-Blind, Multicenter Study. Clinical Infectious Diseases [In-ternet]. Oxford University Press (OUP); 2001 Feb 1;32(3):402–12. Available from: http://dx.doi.org/10.1086/318486

Molinari M, Mangano R, Gough M et al. Linezolid in the treatment of streptococcal skin and soft tissue infections: combined results from three Phase III trials. Clin Microbiol Infect 2000; 6 : 64

Takoudju E, Bémer P, Touchais S, Asseray n, Corvec S, Khatcha-tourian L, et al. Bacteriological relevance of linezolid vs. van-comycin in postoperative empirical treatment of osteoarticular infections: a retrospective single-center study. International Journal of Antimicrobial Agents [Internet]. Elsevier BV; 2018 nov;52(5):663–6. Available from: http://dx.doi.org/10.1016/j. ijantimicag.2018.04.022

Kuandykov TK., Mutagirov VV, Kozhin A. Clinical experience with the use of linezolid in surgical patients. Medicine (Almaty). 2018; 4: 152–154.

Itani KMF, Dryden MS, Bhattacharyya H, Kunkel MJ, Baruch AM, Weigelt JA. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections prov-en to be caused by methicillin-resistant Staphylococcus aureus. The American Journal of Surgery [Internet]. Elsevier BV; 2010 Jun;199(6):804–16. Available from: http://dx.doi.org/10.1016/j. amjsurg.2009.08.045

Efremenkova OV, Belousov YB. Linezolid is the first drug in a new class of antibacterial agents, oxazolidinones. Good clinical prac-tice. 2008; 2: 2–11.

Використання лінезоліду для лікування хірургічних інфекційних ускладнень в умовах антибіотикорезистентності

Published

2021-03-11

How to Cite

1.
Nazarchuk OA, Vitkovskiy VL, Babina YM. Use of Linezolid in the treatment of surgical infectious complications under antibiotic resistance. prmd [Internet]. 2021Mar.11 [cited 2021Apr.11];3(2):34-9. Available from: https://perioperative.org.ua/index.php/prtmdc/article/view/51

Issue

Section

Clinical thinking